SL
Siren LLC Portfolio holdings
AUM
$1.93B
This Quarter Return
+73.94%
1 Year Return
+118.08%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$2.26B
AUM Growth
+$2.26B
(+13%)
Cap. Flow
+$139M
Cap. Flow
% of AUM
6.12%
Top 10 Holdings %
Top 10 Hldgs %
48.55%
Holding
132
New
22
Increased
22
Reduced
21
Closed
14
Top Buys
| 1 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$50.4M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$38.9M |
| 3 |
Apogee Therapeutics
APGE
|
$33.9M |
| 4 |
NewAmsterdam Pharma
NAMS
|
$30.2M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$25.8M |
Top Sells
| 1 |
Scholar Rock
SRRK
|
$86.8M |
| 2 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$30.1M |
| 3 |
Wave Life Sciences
WVE
|
$24.4M |
| 4 |
argenx
ARGX
|
$17.6M |
| 5 |
Biohaven
BHVN
|
$14.2M |
Sector Composition
| 1 | Healthcare | 92.88% |
| 2 | Technology | 3.51% |
| 3 | Communication Services | 1.85% |
| 4 | Consumer Discretionary | 0.74% |
| 5 | Real Estate | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Revolution Medicines
RVMD
$7.21B
| $25M | 1.1% |
571,548
-182,053
| -24% | -$7.96M |
|
27
Vaxcyte
PCVX
$4.03B
| $24.6M | 1.08% |
299,991
| – | – |
|
28
Arcus Biosciences
RCUS
$1.14B
| $24M | 1.06% |
1,612,077
| – | – |
|
29
Erasca
ERAS
$454M
| $22.2M | 0.98% |
8,857,179
| – | – |
|
30
Stoke Therapeutics
STOK
$1.1B
| $22.1M | 0.97% |
+2,000,000
| New | +$22.1M |
|
|
IGMS
31
DELISTED
IGM Biosciences
IGMS
| $20.3M | 0.9% |
3,330,422
| – | – |
|
32
Edgewise Therapeutics
EWTX
$1.53B
| $19.6M | 0.87% |
734,343
+330,230
| +82% | +$8.82M |
|
|
SLN
33
Silence Therapeutics
SLN
$231M
| $19.5M | 0.86% |
2,831,770
| – | – |
|
34
Cytokinetics
CYTK
$5.75B
| $18.9M | 0.84% |
402,323
-123,648
| -24% | -$5.82M |
|
35
Denali Therapeutics
DNLI
$2.2B
| $17M | 0.75% |
834,028
| – | – |
|
36
Korro Bio
KRRO
$197M
| $15.9M | 0.7% |
418,833
| – | – |
|
37
Soleno Therapeutics
SLNO
$3.6B
| $15.8M | 0.7% |
+351,818
| New | +$15.8M |
|
38
Prothena Corp
PRTA
$442M
| $15.2M | 0.67% |
1,099,840
| – | – |
|
39
Solid Biosciences
SLDB
$422M
| $15M | 0.66% |
3,749,041
+1,000,000
| +36% | +$4M |
|
40
Cullinan Oncology
CGEM
$451M
| $14.8M | 0.65% |
1,211,357
| – | – |
|
|
UPB
41
Upstream Bio, Inc. Common Stock
UPB
$968M
| $13.2M | 0.58% |
+800,000
| New | +$13.2M |
|
42
Trevi Therapeutics
TRVI
$887M
| $12M | 0.53% |
+2,906,060
| New | +$12M |
|
43
Kura Oncology
KURA
$698M
| $11.7M | 0.52% |
1,339,942
| – | – |
|
44
Taysha Gene Therapies
TSHA
$783M
| $11.4M | 0.5% |
6,602,475
+1,722,600
| +35% | +$2.98M |
|
45
Remitly
RELY
$3.89B
| $11.1M | 0.49% |
490,449
+465,449
| +1,862% | +$10.5M |
|
46
Cartesian Therapeutics
RNAC
$261M
| $10.2M | 0.45% |
572,236
| – | – |
|
47
Microsoft
MSFT
$3.72T
| $9.69M | 0.43% |
23,000
+1,000
| +5% | +$422K |
|
48
Janux Therapeutics
JANX
$1.36B
| $9.37M | 0.41% |
+175,000
| New | +$9.37M |
|
49
Seer Inc
SEER
$114M
| $9.24M | 0.41% |
4,000,000
| – | – |
|
50
Ionis Pharmaceuticals
IONS
$9.09B
| $8.74M | 0.39% |
250,000
| – | – |
|